Comments
Natco Pharma Ltd’s consolidated net profit more than doubled at Rs 177 crore in the fourth quarter ended March 31, 2017 compared to Rs 63 crore in the corresponding quarter of the previous financial year.
The total revenue of the Hyderabad-based company grew by 46.2 per cent at Rs 577 crore as against Rs 395 crore in the year-ago period.
For the year ended March 2017 too, net profit more than doubled at Rs 486 crore (Rs 157 crore). The revenue went up by 91 per cent at Rs 2,079 crore (Rs 1,090 crore).
"The revenue and profit growth for the company during the financial year was driven primarily by the sales of generic Oseltamivir product in the US market and continued growth domestic formulations business,’’ the company said in a release issued here on Tuesday.
Natco Pharma’s scrip gained 5.70 per cent on the Bombay Stock Exchange on Tuesday to end at Rs 939.65.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.